Dr Paul Richardson is a board-certified hematologist and medical oncologist, at Dana-Farber Cancer Institute (DFCI). After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at (DFCI), Dr Richardson joined the Jerome Lipper Myeloma Center in 1999, was then appointed Clinical Director in 2001. He led the development of several first- and second-generation novel drugs, including bortezomib, lenalidomide, and later pomalidomide, for the treatment of multiple myeloma (MM). Subsequent studies have also focused on next-generation novel drugs including panobinostat and proteasome inhibitors, including the orally bioavailable agent ixazomib.
Primary Specialty
Oncologist
GenderMale
EducationUniversity of London, St. Bartholomew's Medical College
CertificationInternal Medicine, Internal Medicine, Internal Medicine
ServicesDana-Farber Cancer Institute provides oncology services in Boston, MA. Oncology includes the diagnosis and treatment of breast cancer, skin cancer, prostate cancer, and many other forms of cancer.
Contact Paul Richardson, MD at (877) 442-3324 for specific information about cancer treatment in Boston, MA.